|
Balance Sheet Cash Flow Statement 100 Campus Dr. Marlborough, MA 01752 MA Tel. 508-683-1200 Fax 508-683-1201 |
Type: Public
On the web:
http://www.exactlabs.com
Employees:
4
Employee growth: (71.4%)
Guesstimates aren't good enough when diagnosing a deadly cancer, so EXACT Sciences aims for accuracy. The firm develops non-invasive tests for the early detection of colorectal cancer and precancerous lesions. Its products isolate DNA in stool samples, using its Effipure technology, then identify genetic mutations associated with cancer. Colorectal cancer is a common (and one of the deadliest) cancers, and EXACT believes its method is superior to existing diagnostic methods because it may be able to discern colorectal cancer in its early stages, when it is most treatable. However, facing several product development setbacks, the company is undergoing a strategic reorganization.
Key numbers for fiscal year ending December, 2008:
Sales: ($0.9)M
Net income: ($9.7)M
Officers:
Chairman: Patrick J. (Pat) Zenner
President, CEO, and Director: Kevin T. Conroy
SVP and CFO: Maneesh K. Arora
Competitors:
CRH Medical
PreMD
Radient Pharmaceuticals
